SARS-CoV-2 Spike V483A mutant Cell Line from Innoprot stable expresses SARS-CoV-2 Spike Glycoprotein encoding a V483A mutation. Coronaviruses (CoVs) infect human and animals and cause varieties of diseases, such as respiratory, enteric, renal, and neurological diseases. At the end of 2019, a novel coronavirus, named SARS-CoV-2, was found in patients with severe pneumonia in Wuhan, China. It is is now spreading across the globe. V483A mutation has the potential to change the protein secondary structure and relative solvent accessibility in the RBM region.
SARS-CoV-2 uses its spike glycoprotein (S), a main target for neutralization antibody, to bind its receptor, and mediate membrane fusion and virus entry. It uses hACE2 to enter cells, correlating with the efficient spread of SARS-CoV-2 among humans. S comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and also fusion of the viral and cellular membranes (S2 subunit). SARS-CoV-2 Spike Glycoprotein Cell Line cell line allows the study of SARS-CoV-2 spike/ACE2 interaction in cell-based assays.
Click here to get more information about SARS-CoV-2 Spike Glycoprotein.
Click here to get more information about V483A mutation.
